8-K
filed March 26, 2026, 7:59 PM ET
ticker IRIX
CIK 0001006045
earnings
confidence high
sentiment positive
materiality 0.70
Iridex Q4 revenue $14.7M up 16% YoY; first positive adjusted EBITDA
IRIDEX CORP
- Q4 total revenue $14.7M (+16% YoY); retina $8.9M (+22%), Cyclo G6 $3.8M (+15%).
- Q4 net loss improved to $0.2M ($0.01 EPS) from $0.8M ($0.05 EPS) in Q4 2024.
- FY 2025 revenue $52.7M (+8% YoY); net loss $4.4M ($0.26) vs $8.9M ($0.54) in 2024.
- First positive adjusted EBITDA of $1.1M in FY 2025 (vs -$4.3M in 2024) and Q4 $0.8M.
- FY 2026 guidance: revenue $51M-$53M; positive operating cash flow; OpEx $19M-$19.5M.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
IRIDEX CORP reported FY 2026 results: revenue $51 million to $53 million.
- Period
- FY 2026
- Revenue
- $51 million to $53 million
- Result
- guidance update
Exact text from the filing
The Company currently forecasts 2026 revenue of between $51 million and $53 million.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
IRIDEX CORP reported Q4 2025 (three months ended January 3, 2026) results: revenue $14.7 million, net income Net loss was $0.2 million, EPS $0.01 per share.
- Period
- Q4 2025 (three months ended January 3, 2026)
- Revenue
- $14.7 million
- Net income
- Net loss was $0.2 million
- EPS
- $0.01 per share
- Result
- reported results
Exact text from the filing
Revenue for the three months ended January 3, 2026 was $14.7 million, representing a 16% year-over-year increase compared to the fourth quarter of 2024.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
IRIDEX CORP reported Q4 2025 (three months ended January 3, 2026) results: revenue $14.7 million, net income Net loss was $0.2 million, EPS $0.01 per share.
- Period
- Q4 2025 (three months ended January 3, 2026)
- Revenue
- $14.7 million
- Net income
- Net loss was $0.2 million
- EPS
- $0.01 per share
- Result
- reported results
Exact text from the filing
diseases, today reported financial results for the fourth quarter and full year ended January 3, 2026. Fourth Quarter 2025 Financial Highlights • Generated total revenue of $14.7 million, representing growth of 16% year-over-year compared to $12.7 million in the prior year quarter • Cyclo G6® product family revenue was $3.8 million, representing growth of 15%
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
IRIDEX CORP reported Full year 2025 (year ended January 3, 2026) results: revenue $52.7 million, net income Net loss for 2025 improved to $4.4 million, EPS $0.26 per share.
- Period
- Full year 2025 (year ended January 3, 2026)
- Revenue
- $52.7 million
- Net income
- Net loss for 2025 improved to $4.4 million
- EPS
- $0.26 per share
- Result
- reported results
Exact text from the filing
Revenue for the year ended January 3, 2026 was $52.7 million, representing growth of 8% compared to $48.7 million in 2024.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.99
IRIDEX CORP reported Full year 2025 (year ended January 3, 2026) results: revenue $52.7 million, net income Net loss for 2025 improved to $4.4 million, EPS $0.26 per share.
- Period
- Full year 2025 (year ended January 3, 2026)
- Revenue
- $52.7 million
- Net income
- Net loss for 2025 improved to $4.4 million
- EPS
- $0.26 per share
- Result
- reported results
Exact text from the filing
year period • Cash and cash equivalents as of January 3, 2026 were $6.0 million, an increase of $0.4 million in the quarter. Full Year 2025 Results • Generated total revenue of $52.7 million, compared to $48.7 million in 2024, representing growth of 8% • Cyclo G6® Glaucoma product family revenue of $13.8 million, compared to $12.7 million in 2024 o Sold 57,800 Cyclo
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.